Loading clinical trials...

A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa | Clinical Trials | Clareo Health

WITHDRAWNPHASE2

A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa

An Exploratory, Cross-Over Study of the Safety of HP802-247 Applied to Open Wounds of Subjects With Dystrophic Epidermolysis Bullosa

NCT01528306•Healthpoint

View on ClinicalTrials.gov

Summary

This is a pilot study designed to see if HP802-247, an investigational treatment with living human skin cells, helps to heal blisters or wounds in subjects with Dystrophic Epidermolysis Bullosa (DEB). The durability of the skin in healed wounds treated with HP802-247 will also be assessed.

Eligibility

Age

2 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Written consent must be obtained from a parent or legally authorized representative. Assent will be obtained according to local requirements.
•Subjects with a clinical diagnosis of DEB with recurring blisters, ≥ 2 years of age at Screening. Subjects may be of either sex and of any race or skin type provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
•A parent or legally authorized representative must be willing and able to ensure subject is present for all required study visits.
•A parent or legally authorized representative must be able to follow instructions.
•Have an open wound for ≤ 72 hours that:
•* is still open and has not scabbed or crusted over
•* has no dermatologic disease and/or condition in the treatment area (other than DEB with recurring blisters), including active or recent infection (within 7 days) that may be exacerbated by treatment, require treatment with antibiotics / antifungals /antivirals, require a surgical intervention, or cause difficulty with examination
•* is ≥ 4 cm² and ≤ 48 cm2 in total area (open portion)
•Females of childbearing potential (defined as post-menarcheal as documented in the medical history) may participate in the study if they meet all of the following conditions:
•* they are not breast feeding;
+6 more criteria

Exclusion Criteria

•Contraindications or hypersensitivity to the use of the test article, their components (e.g., aprotinin, fibrinogen), or substances used in the manufacture of the test article (e.g., penicillin, streptomycin, amphotericin B, bovine serum albumin).
•Therapy with another investigational agent within thirty (30) days of the Screening Visit, or during the study.
•Have uncontrolled intercurrent or chronic illness that, in the opinion of the Investigator, would limit compliance with study requirements, represents a potential safety risk, or require treatment with an excluded drug/treatment.
•The Investigator or Medical Monitor may declare any subject ineligible for a valid medical reason.

Key Dates

Start Date

March 1, 2012

Primary Completion Date

March 1, 2013

Completion Date

July 1, 2013

Last Updated

May 16, 2012

Conditions

Dystrophic Epidermolysis Bullosa

Interventions

HP802-247

BIOLOGICAL

Placebo

OTHER

Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa

NCT05157958

Dystrophic Epidermolysis Bullosa

View study

ACTIVE_NOT_RECRUITINGPHASE3

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

NCT04213261

Recessive Dystrophic Epidermolysis Bullosa

View study

ACTIVE_NOT_RECRUITINGPHASE3

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

NCT06892639

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 16, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa

Inclusion Criteria

Exclusion Criteria

Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

Pilot Study of ELK-003 Eye Drops for Treating Ocular Manifestations of Epidermolysis Bullosa

A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)